---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: CT-AMT-130-02"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: CT-AMT-130-02. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 32 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence/ct-amt-130-02"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: CT-AMT-130-02

<a id="heading-3.1.3"></a>

## 3.1.3 CT-AMT-130-02

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Primary and secondary objectives in the EU Clinical Trials Register

> “Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult participants with early manifest HD”
> “Determine the duration of persistence of AMT-130 in the brain”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.1-2"></a>

#### Expanding exposure to both doses after the U.S. study

> “The aim of the European study is to build upon the safety demonstrated in the first human dose (FHD) randomized, double blind, sham-controlled sequential dose escalation study (CT-AMT-130-01; clinicaltrials.gov NCT04120493) being conducted in the US and expand the number of patients exposed to the two doses to provide sufficient sample size for comparisons of safety and efficacy.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.1-3"></a>

#### Dose selection for later development, March 2022

> “Together with the U.S. study, the European study is intended to establish safety, proof of concept, and the optimal dose of AMT-130 to take forward into a pivotal study or into a confirmatory study should an accelerated registration be feasible.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Sites in Poland, the United Kingdom, and Germany at first dosing, February 2022

> “The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany.”
> “The study is currently open for recruitment at IPiN and surgery at INC in Poland and is expected to expand to referral and surgical sites in the United Kingdom and Germany.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="topic-3.1.3.2-2"></a>

#### Study sites and dates in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Site, Warsaw, Poland | “Instytut Psychiatrii i Neurologii” |
| Site, Warsaw, Poland | “Interventional Neuro Center” |
| Site, Cardiff, United Kingdom | “Cardiff University” |
| Site, London, United Kingdom | “National Hospital for Neurology & Neurosurgery” |
| Study start (actual) | “2021-10-07” |
| Primary completion (estimated) | “2029-03” |
| Study completion (estimated) | “2029-10-07” |

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.2-3"></a>

#### EU trial record after transition to the Clinical Trials Regulation

| Field | Record value |
| --- | --- |
| Protocol code | “CT-AMT-130-02” |
| Transition trial | “Yes” |
| Locations | “Poland” |
| Start of trial | “Start of trial 07/10/2021” |
| Current status in Poland | “Ongoing, recruitment ended” |
| Recruitment end in Poland | “15/10/2024” |
| Estimated global end date | “31/12/2029” |

Source: [CTIS 2024-511766-37-00](https://euclinicaltrials.eu/ctis-public/view/2024-511766-37-00)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Open-label Cohorts 1 and 2 and randomized Cohort 3 in the current registry record

> “CT-AMT-130-02 is a Phase Ib/II open-label (Cohorts 1 & 2), randomized (Cohort 3 only) sequential multiple dose study that will be conducted in approximately 5 to 8 European HD centers; 2 of these centers will serve as surgical sites.”
> “Both studies will share a common set of clinical, safety, imaging, and biomarker evaluations over 5 years of follow-up.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.3-2"></a>

#### Design fields in the current registry record

| Field | Registry value |
| --- | --- |
| Official title | “A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease” |
| Allocation | “Randomized” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.3-3"></a>

#### Non-randomized, open-label ascending-dose design: registry version 1, February 2022, superseded

| Field | Registry value |
| --- | --- |
| Version | “Viewing V1 (2022-02-07)” |
| Official title | “A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington Disease” |
| Masking | “None (Open Label)” |
| Allocation | “Non-Randomized” |
| Enrollment | “15 [Estimated]” |

Source: [ClinicalTrials.gov NCT05243017 version 1](https://clinicaltrials.gov/study/NCT05243017?tab=history&a=1)

> “The first cohort will be treated with low dose, and a total of 6 enrolled participants is anticipated. The second cohort will be treated with high dose, and a total of 9 enrolled participants is anticipated.”

Source: [ClinicalTrials.gov NCT05243017 version 1](https://clinicaltrials.gov/study/NCT05243017?tab=history&a=1)

<a id="topic-3.1.3.3-4"></a>

#### Trial design fields in the EU Clinical Trials Register

| Field | Register value |
| --- | --- |
| Controlled | “No” |
| Randomised | “No” |
| Open | “Yes” |
| Double blind | “No” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.3-5"></a>

#### Six-month post-treatment period followed by five years of follow-up

> “The multi-center study consists of an initial 6-month post-treatment study period followed by long-term follow-up for five years.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Inclusion criteria in the EU Clinical Trials Register

> “Male and female participants 25 to 65 years of age.”
> “Cohorts 1 & 2: Early manifest HD as defined by a UHDRS TFC score of 9 to 13 and EITHER”
> “Cohort 3: Early manifest HD as defined by a UHDRS TFC score of ≥11 and EITHER”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.4-2"></a>

#### Genetic and striatal volume criteria in the current registry record

> “HTT gene expansion testing with the presence of ≥40 CAG repeats (confirmed by genetic testing at central laboratory).”
> “Putamen ≥2.5 cm3 (per side)”
> “Caudate ≥2.0 cm3 (per side)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.4-3"></a>

#### Exclusion criteria: suicide attempt within 1 year

> “Suicide attempt within 1 year prior to Screening (Visit 1/1A)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.4-4"></a>

#### Same early manifest criteria as the U.S. study

> “The multi-center, open-label, Phase I/II clinical trial of AMT-130 being conducted in Europe and the UK enrolled a total of 13 patients with the same early manifest criteria for Huntington’s disease as the U.S. study.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Doses by cohort in the current registry record

> “Low dose AMT-130 (6 × 10^12 gc/subject)”
> “High dose AMT-130 (6 × 10^13 gc/subject)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.5-2"></a>

#### Investigational product concentration in the EU Clinical Trials Register

| Field | Register value |
| --- | --- |
| Concentration number | “2 x 10e13 gc/mL” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.5-3"></a>

#### All participants dosed with AMT-130

> “All patients will be dosed with AMT-130.”
> “Patients will receive a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Safety Measures as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Integrated two-study program with staggered enrollment under one safety board

> “This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.”
> “The DSMB will evaluate safety and other parameters to enable the staggered treatment of patients within each of the dosing cohorts”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.6.1-2"></a>

##### Primary outcomes at 6 months in the ClinicalTrials.gov record

> “Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Adverse Events”
> “Type and incidence of Adverse Events (AEs)”
> “Change over time in microglial activation (YKL-40) (pg/mL)”
> “Change over time in antibodies against AAV5 (g/L)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.6.1-3"></a>

##### Primary end points in the EU Clinical Trials Register

> “Prospective assessment of suicidality via the Columbia-Suicide Severity Rating Scale (C-SSRS).”
> “Change from baseline to Day 14 and Month 1 in the Montreal Cognitive Assessment (MoCA)”
> “Change from baseline in edema, inflammation, volume loss, and structural changes as measured by the following MRI pulse sequences: T1, T2, and diffusion MRI (dMRI).”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.6.1-4"></a>

##### Secondary end points: vector DNA and miRNA expression in cerebrospinal fluid

> “Change over time in levels of AMT-130-derived vector DNA and miRNA expression in the CSF in Cohorts 1 and 2 through approval of CT-AMT-130-02 Protocol Amendment 6.0 Version 7.0.”
> “Change over time in levels of only AMT-130 derived vector DNA in Cohorts 1 and 2 post-approval and throughout the trial in Cohort 3.”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment of 15 participants in two open-label cohorts, February 2022

> “The European Phase Ib/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, proof of concept, and dosing in 15 total patients with early manifest Huntington’s disease split into a six person, low-dose open-label cohort, followed by a nine patient, higher-dose open-label cohort.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="topic-3.1.3.7.1-2"></a>

##### Participants enrolled and treated by dose

> “In the European study, 13 patients were enrolled and treated with AMT-130 (six low-dose patients and seven high-dose patients).”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.3.7.1-3"></a>

##### Actual enrollment in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Enrollment (actual) | “14” |

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### First two participants dosed, February 2022

> “today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="topic-3.1.3.8.1-2"></a>

##### Participants treated, November 2022

> “To date, 10 patients have been treated in the European study, including all six patients in the lower-dose cohort and four of nine patients in the higher-dose cohort.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-3.1.3.8.1-3"></a>

##### Enrollment completed in June 2023

> “We completed the enrollment of all 26 patients in the first two cohorts of the U.S. study in March 2022 and the enrollment of 13 patients in the first two cohorts of the European study in June 2023.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Suspected unexpected serious adverse reactions in two high-dose participants at one site, July 2022

> “In mid-July, the Company reported to the appropriate regulatory agencies suspected unexpected severe adverse reactions (SUSARs) in two patients that were treated with the higher-dose of AMT-130 at a single clinical site in the European Phase Ib/II study.”
> “Both patients presented with localized inflammatory responses and other related symptoms approximately one to two weeks after their procedures.”
> “All three patients have fully or substantially recovered after treatment and have been released from the hospital.”

Source: [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and)

<a id="topic-3.1.3.8.5-2"></a>

##### Plan to resume dosing in the European study, November 2022

> “The Company plans to resume patient dosing in the open-label European clinical study as soon as possible and complete enrollment in the first half of 2023.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-3.1.3.8.5-3"></a>

##### Safety notifications in the EU trial record

| Notification | Record value |
| --- | --- |
| Serious breach | “Serious Breach (0)” |
| Unexpected event | “Unexpected Event (0)” |
| Urgent safety measure | “Urgent Safety Measure (0)” |
| Temporary halt | “Temporary Halt (0)” |

Source: [CTIS 2024-511766-37-00](https://euclinicaltrials.eu/ctis-public/view/2024-511766-37-00)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

- Open-label, uncontrolled design with inconsistent records: the EU Clinical Trials Register lists the trial as not controlled, not randomised, open, and not double blind. The ClinicalTrials.gov record describes open-label Cohorts 1 and 2 and randomization in Cohort 3 only, lists allocation as randomized and masking as none (open label), and gives an official title describing a randomized, double-blind study; version 1 (2022) listed a non-randomized, open-label design with an estimated enrollment of 15.
- Enrollment: 15 participants were planned (six low dose, nine high dose). The Form 10-K reports 13 participants enrolled and treated (six low dose, seven high dose), while the ClinicalTrials.gov record lists an actual enrollment of 14.
- Sites: the February 2022 release named sites in Poland, the United Kingdom, and Germany; the ClinicalTrials.gov record lists sites in Poland and the United Kingdom, and the CTIS record lists Poland.
- Results reporting: the pooled-analysis protocols pool data across the U.S. and EU studies, and the registered primary outcomes are safety and tolerability measures, including adverse events.
- Safety: suspected unexpected severe adverse reactions occurred in two high-dose participants treated at a single clinical site.

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL); [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017); [ClinicalTrials.gov NCT05243017 version 1](https://clinicaltrials.gov/study/NCT05243017?tab=history&a=1); [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [CTIS 2024-511766-37-00](https://euclinicaltrials.eu/ctis-public/view/2024-511766-37-00); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
